Lecanemab Receives Full FDA Approval for Early Alzheimer's Disease

The FDA granted traditional (full) approval to lecanemab (Leqembi) for early Alzheimer's disease, following confirmatory Phase 3 data showing 27% slowing of cognitive decline.